Large-vessel vasculitis (LVV) manifests as inflammation of the aorta and its major branches
and is the most common primary vasculitis in adults. LVV comprises two distinct conditions …

Cardiovascular toxicities associated with immune checkpoint inhibitors (ICIs) have been
reported in case series but have been underappreciated due to their recent emergence …

Objectives To evaluate the prevalence and type of rheumatic immune-related adverse
events (irAEs) in patients receiving immune checkpoint inhibitors (ICIs), as well as the …

Immune checkpoint inhibitors have proven to be efficacious for a broad spectrum of solid
organ malignancies. These monoclonal antibodies lead to cytotoxic T-cell activation and …

Cancer therapies can lead to a broad spectrum of cardiovascular complications. Among
these, cardiotoxicities remain of prime concern, but vascular toxicities have emerged as the …

Recent experimental and genetic studies have implicated the role of programmed cell death
protein 1 (PD-1), programmed cell death protein-ligand 1 (PDL-1), and cytotoxic T …

Immunotherapy has revolutionized the treatment of cancer, but a rapid rise in the use of the
family of therapeutic agents known as checkpoint inhibitors (CPIs) is associated with a new …

The fields of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) have advanced
rapidly, resulting in a new understanding of these diseases. Fast-track strategies and …

Objectives Immune checkpoint inhibitors (ICIs) targeting cytotoxic T-lymphocyte-associated
protein 4 and programmed cell death protein 1 (PD-1) have demonstrated improved survival …

Background: Giant cell arteritis, a chronic autoimmune disease of the aorta and its large
branches, is complicated by aneurysm formation, dissection, and arterial occlusions. Arterial …